PF-Atlas › Clinical Trials › NCT00457821
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
Ivacaftor 25 mg/75 mg · Phase 2
Registry ID
NCT00457821
Phase
Phase 2
Status
Completed
Drug / intervention
Ivacaftor 25 mg/75 mg
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2007-05
Enrollment
39
Locations
15
About this trial
The purpose of this study was to evaluate the safety and tolerability of ivacaftor in patients with cystic fibrosis (CF) who were aged 18 years or older and have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a potent and selective CFTR potentiator of wild-type, G551D, F508del, and R117H forms of human CFTR protein. Potentiators are pharmacological agents that increase the chloride ion transport properties of the channel in the presence of cyclic AMP-dependent protein kinase A (PKA) activation.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00457821 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.